Symposium Satellite HER2+ Early Breast Cancer Therapy:

HER2+ Early Breast Cancer Therapy:
Good, Better, Best - Never Let it Rest!
Friday, April 21 – 3:45-5:15 p.m.
Cascade Room, The Fairmont Banff Springs
Dr. Anil Abraham Joy MD, FRCPC
Professor, Department of Oncology, Division of Medical Oncology, University of Alberta
Medical Oncologist, Cross Cancer Institute, Edmonton, Alberta, Canada
Colleen Olson BA, BSP
Senior Oncology Pharmacist, Saskatoon Cancer Centre
Breast cancer remains the most commonly diagnosed cancer in women and is the leading
cause of cancer-related deaths. Despite current advances in HER2-positive early breast cancer
treatments, up to one in three women with HER2-positive early breast cancer will develop
metastatic disease. This session will focus on the evolution of HER2-targeted therapies in
early breast cancer and the potential role of novel agents in HER2-positive breast cancer
from the perspective of a multi-disciplinary team.
Learning Objectives:
1. Review the historical outcomes in the pre-trastuzumab era, the trastuzumab revolution
and optimization of trastuzumab therapy
2. Examine the role of novel agents/therapeutic strategies in early HER2-positive
breast cancer
3. Understand the mechanism of action, common toxicities, and pharmacy
consideration in administration of HER-targeted therapies
4. Discuss the role of pharmacists in early
breast cancer patient practice
CAPhO Conference 2017
Support for this satellite symposium is provided by
Hoffmann-La Roche Limited, Mississauga, ON L5N 5M8
Canadian Association of Pharmacy in Oncology
April 20 – 23, 2017
The Fairmont Banff Springs Hotel, Banff, Alberta
Random flashcards

4 Cartes mariam kasouh

Le lapin

5 Cartes Christine Tourangeau

découpe grammaticale

0 Cartes Beniani Ilyes

Anatomie membre inf

0 Cartes Axelle Bailleau

Créer des cartes mémoire